Methods and compositions for modulating tweak and fn14 activity
AssigneeGenentech, Inc.
InventorsAVI J. ASHKENAZI, Heather Maecker
Life of this patent
Estimating the term…
Abstract
Agonists and antagonists which modulate the activity of TWEAK and TWEAK receptor are provided. The methods, compositions and kits of the invention may be employed in the treatment of disorders such as cancer and immune-related diseases.
Claims35
A method of treating cancer, comprising exposing mammalian cancer cells to an effective amount of an antagonist molecule, wherein said antagonist is selected from the group consisting of
- q) anti-TWEAK antibody;
- r) anti-TWEAK receptor antibody;
- s) TWEAK receptor immunoadhesin;
- and
- t) agent or molecule which blocks or interrupts intracellular signaling of TWEAK receptor.
A method of enhancing NK cell activity in a mammal, comprising administering to said mammal to an effective amount of an antagonist molecule, wherein said antagonist is selected from the group consisting of
- u) anti-TWEAK antibody;
- v) anti-TWEAK receptor antibody;
- w) TWEAK receptor immunoadhesin;
- and
- x) agent or molecule which blocks or interrupts intracellular signaling of TWEAK receptor.
A method of enhancing innate TH1 responses or activity in a mammal, comprising administering to said mammal an effective amount of an antagonist molecule, wherein said antagonist is selected from the group consisting of
- y) anti-TWEAK antibody;
- z) anti-TWEAK receptor antibody;
- aa) TWEAK receptor immunoadhesin;
- and
- bb) agent or molecule which blocks or interrupts intracellular signaling of TWEAK receptor.
A method of treating a TH2 mediated disorder in a mammal, comprising administering to said mammal an effective amount of an antagonist molecule, wherein said antagonist is selected from the group consisting of
- cc) anti-TWEAK antibody;
- dd) anti-TWEAK receptor antibody;
- ee) TWEAK receptor immunoadhesin;
- and
- ff) agent or molecule which blocks or interrupts intracellular signaling of TWEAK receptor.
A method of treating an immune-related disorder, comprising administering to a mammal an effective amount of an agonist molecule, wherein said agonist is selected from the group consisting of:
- a) anti-TWEAK receptor antibody;
- b) TWEAK polypeptide;
- and
- c) TWEAK polypeptide variant.
Dependencies are inferred from the claim text.